DC-VACCINE_IRSTIRCCS

DRUG4 trials

Sponsors

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Conditions

GlioblastomaMetastatic colorectal cancerStage IV colorectal cancerneuroendocrine tumorssoft tissue sarcoma

Phase 2

Vaccination with Autologous Dendritic cells loaded with Autologous Tumour homogenate in Glioblastoma: a phase II Study (Combi G-Vax)

RecruitingCTIS2024-512493-98-00

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.Glioblastoma

Start: 2021-03-25Target: 28Updated: 2024-07-15

A phase II study on adjuvant vaccination with dendritic cells loaded with autologous tumor homogenate in resected stage IV rare cancers: neuroendocrine tumors (NET) and soft tissue sarcoma (STS).

RecruitingCTIS2023-510251-31-00

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.neuroendocrine tumors, soft tissue sarcoma

Start: 2019-12-12Target: 30Updated: 2024-07-17

Vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer: a phase II study (COREVAX-1)

RecruitingCTIS2024-516221-31-00

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.Stage IV colorectal cancer

Start: 2016-04-19Target: 19Updated: 2024-09-16

Sequential immunochemotherapy treatment with Pembrolizumab plus Dendritic Cell (DC) Vaccine followed by Trifluridine/Tipiracil plus Bevacizumab in refractory mismatch-repair-proficient (pMMR) or microsatellite-stable (MSS) metastatic colorectal cancer

RecruitingCTIS2024-514053-30-00

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.Metastatic colorectal cancer

Start: 2025-01-07Target: 36Updated: 2024-11-07